Drugs / Dexanabinol

Trials 5 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT02423239 Apr 2015 → Dec 2016 hepatocellular carcinoma, malignant exocrine pancreas neoplasm e-Therapeutics PLC Unknown No outcome recorded
Phase 1 NCT02054754 Jan → Sep 2014 cancer e-Therapeutics PLC Completed No outcome recorded
Phase 1 NCT01654497 Jun 2012 → Sep 2015 brain cancer Santosh Kesari, M.D., Ph.D. Completed No outcome recorded
Phase 1 NCT01489826 Jan 2012 → Jul 2015 cancer e-Therapeutics PLC Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00129857 Jan 2001 → Sep 2004 traumatic brain injury Pharmos Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Dexanabinol ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489826
4

NCT01654497

NCT02423239

NCT00129857

NCT02054754

Known as HU-211 ChEMBL registry synonym — accepted as the source's own label CHEMBL334533
Known as PA-50211 ChEMBL registry synonym — accepted as the source's own label CHEMBL334533
Known as PRS-211007 ChEMBL registry synonym — accepted as the source's own label CHEMBL334533
Known as PRS-211007-000 ChEMBL registry synonym — accepted as the source's own label CHEMBL334533
Known as Sinnabidol ChEMBL registry synonym — accepted as the source's own label CHEMBL334533
Action Inhibit “It combines the ability to block NMDA receptors and neuroinflammatory cascades in the same molecule.” NCT00129857
Modality Small molecule “dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity” PMID 16361021 Jan 2006
Route Intravenous “a single intravenous 150 mg dose of dexanabinol or placebo” PMID 16361021 Jan 2006